Phase II
Teva has a new headache. As the company pushes forward with its cost-cutting strategies, the company reported it is scrapping its chronic cluster headache program with fremanezumab.
Epizyme Posts Positive Interim Data for Follicular Lymphoma Treatment, Despite Partial Clinical Hold
Despite some of the troubles Epizyme has seen with its lead drug candidate tazemetostat, including a partial clinical hold placed by the U.S. Food and Drug Administration, the company is pushing forward with positive interim data presented at the 23rd Congress of the European Hematology Association.
Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.
Bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.
Flex Pharma announced in a Corporate Update that it is closing an ongoing Phase II clinical trial of FLX-787 in ALS and CMT while shifting its strategy to focus on other approaches.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
Allergan announced positive results from its oral Phase IIb/III CGRP antagonist, atogepant. Allergan said atogepant showed a statistically significant reduction in monthly migraine days.
The company said its Phase II herpes drug did not meet its primary endpoints and will terminate the program.
Ironwood Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced the U.S. Food and Drug Administration (FDA) had granted its olinciguat (IW-1701) Orphan Drug Designation for sickle cell disease.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
PRESS RELEASES